Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Profit After Tax: 2014-2025

Historic Profit After Tax for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to -$90.8 million.

  • Viking Therapeutics' Profit After Tax fell 264.02% to -$90.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$237.4 million, marking a year-over-year decrease of 139.43%. This contributed to the annual value of -$110.0 million for FY2024, which is 28.02% down from last year.
  • According to the latest figures from Q3 2025, Viking Therapeutics' Profit After Tax is -$90.8 million, which was down 38.48% from -$65.6 million recorded in Q2 2025.
  • Viking Therapeutics' 5-year Profit After Tax high stood at -$12.4 million for Q4 2021, and its period low was -$90.8 million during Q3 2025.
  • In the last 3 years, Viking Therapeutics' Profit After Tax had a median value of -$24.9 million in 2024 and averaged -$36.2 million.
  • Data for Viking Therapeutics' Profit After Tax shows a maximum YoY plummeted of 264.02% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Viking Therapeutics' Profit After Tax stood at -$12.4 million in 2021, then slumped by 58.30% to -$19.6 million in 2022, then declined by 25.80% to -$24.6 million in 2023, then tumbled by 43.94% to -$35.4 million in 2024, then plummeted by 264.02% to -$90.8 million in 2025.
  • Its last three reported values are -$90.8 million in Q3 2025, -$65.6 million for Q2 2025, and -$45.6 million during Q1 2025.